* This field is required
Immune-Related Skin Diseases
Solutions
Online Inquiry

Immune-Related Skin Diseases

Immune-Related Skin Diseases are disorders resulting from abnormal immune responses that impair skin function and structure. While each condition is individually rare, together they affect many people worldwide, causing severe symptoms and presenting significant healthcare challenges. Our Company, with expertise in this field, is dedicated to advancing research and developing therapies to address these Immune-Related Skin Diseases.

Introduction to Immune-Related Skin Diseases

Immune-Related Skin Diseases are a group of uncommon conditions in which the immune system mistakenly attacks the skin, leading to inflammation and tissue damage. Examples include autoimmune blistering diseases, such as pemphigus and pemphigoid, which have an incidence of 1 to 5 cases per million people per year. These disorders are often chronic and can cause significant morbidity if untreated. Recent advances in immunotherapy have provided new treatment options, though challenges remain in managing these complex conditions.

Pathogenesis of Immune-Related Skin Diseases

The pathogenesis of immune-related skin diseases involves complex interactions between genetic predispositions, environmental factors, and immune system dysregulation. Recent studies have revealed that cytokine imbalances and aberrant T-cell activation play critical roles in conditions such as psoriasis and atopic dermatitis.

Immune imbalance triggers the onset of immune-related skin diseases.Fig.1 Disruption of immune homeostasis leads to the development of immune skin diseases. (Zhang, B., et al., 2024)

Advances in understanding the skin microbiome's influence on immune responses highlight its contribution to disease development and exacerbation. Furthermore, cutting-edge genomic and proteomic technologies are providing insights into novel therapeutic targets, offering hope for more effective and personalized therapeutics.

Mesenchymal Stem Cells Therapy for Immune-Related Skin Diseases

Mesenchymal stem cells (MSC) therapy has shown potential in treating Immune-Related Skin Diseases due to its immunomodulatory and anti-inflammatory properties. MSCs aid in healing skin lesions and promoting re-epithelization by secreting growth factors.

Table.1 Clinical trials of MSC therapy in immune-related skin diseases (Hua, C., S. Chen, and H. Cheng, 2022)

Diseases Development Stage Route of Delivery Type of MSC ClinicalTrials.gov Identifier
Psoriasis Clinical Trial Early Phase 1 Intravenous infusion. Human Umbilical Cord-derived Mesenchymal Stem Cells NCT03765957
Clinical Trial Phase 1, 2 Intravenous infusion. Human Umbilical Cord-derived Mesenchymal Stem Cells NCT03745417
Clinical Trial Phase 1, 2 Subcutaneous injection Human Umbilical Cord-derived Mesenchymal Stem Cells NCT02918123
Systemic Sclerosis Clinical Trial Phase 1 Intravenous Infusion Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell NCT05016804
Clinical Trial Phase 1, 2 Intravenous Infusion Allogeneic Mesenchymal Stem Cells NCT00962923
Atopic Dermatitis Clinical Trial Phase 1 Intravenous Infusion Adult human Mesenchymal Stem Cells NCT02888704
Clinical Trial Phase 1 Intravenous Infusion Adult human Mesenchymal Stem Cells NCT03252340
Clinical Trial Phase 3 Unclear Human Umbilical Cord Blood derived- Universal Stem Cells NCT03269773

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

We provide comprehensive support for developing treatments for rare immune-related skin conditions. Our expert team leverages advanced technology, offering therapeutic development and disease model development services to fast-track your projects.

Therapeutic Development

  • Small Molecule Drug
  • Cell Therapy
  • Gene Therapy
  • Therapeutic Antibody
  • Therapeutic Peptide
  • Therapeutic mRNA
  • Therapeutic Protein

Disease Model Development

  • 2D Cell Models
  • 3D Models
  • Genetically Engineering Model
  • Induced Disease Model
  • Humanized Animal Model
  • Syngeneic Model
  • Xenograft Model

Types of Immune-Related Skin Diseases

With our deep expertise, we are dedicated to advancing the research and development of treatments for Immune-Related Skin Diseases. Recognizing the unique genetic and pathological features of each condition, our team delivers customized solutions to accelerate the discovery and implementation of effective therapies.

A-L M-P S-V
  • Alopecia Areata (AA)
  • Dermatomyositis
  • Generalized Pustular Psoriasis
  • Interstitial Granulomatous Dermatitis
  • Langerhans Cell Histiocytosis (LCH)
  • Livedo Racemosa
  • Livedo Reticularis
  • Mycosis Fungoides (MF)
  • Pemphigus
  • Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin Changes Syndrome (POEMS syndrome)
  • Psoriasis
  • Pyoderma Gangraenosum
  • Sarcoidosis
  • Schnitzler Syndrome
  • Sezary Syndrome (SS)
  • Sweet-Syndrom
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis (SSc)
  • Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VAMAS6)

Our company is focused on providing comprehensive, one-stop preclinical development services to drive the advancement of therapeutics for rare skin diseases. Our integrated solutions simplify the drug development pathway, covering everything from target discovery and disease modeling to thorough drug safety evaluation services and drug metabolism and pharmacokinetics.

If you are interested in our services, please don't hesitate to contact us.

References

  • Alaibac, M. "Immune-Mediated Skin Diseases: Future Therapeutic Perspectives." Medicina (Kaunas) 59.10 (2023).
  • Zhang, B., et al. "The New Era of Immune Skin Diseases: Exploring Advances in Basic Research and Clinical Translations." J Transl Autoimmun 8 (2024): 100232.
  • Hua, C., S. Chen, and H. Cheng. "Therapeutic Potential of Mesenchymal Stem Cells for Refractory Inflammatory and Immune Skin Diseases." Hum Vaccin Immunother 18.6 (2022): 2144667.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.